{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:00:05Z","timestamp":1791907205676,"version":"4.3.4"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cellsig.2024.111426","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:26:41Z","timestamp":1726763201000},"page":"111426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The renin-angiotensin-aldosterone system: An old tree sprouts new shoots"],"prefix":"10.1016","volume":"124","author":[{"given":"Yaqing","family":"Ruan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0005","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/med.21996","article-title":"Diverse biological functions of the renin-angiotensin system","volume":"44","author":"Rao","year":"2024","journal-title":"Med. Res. Rev."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0010","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14164","article-title":"Beyond blood pressure, fluid and electrolyte homeostasis - role of the renin angiotensin aldosterone system in the interplay between metabolic diseases and breast cancer","volume":"240","author":"Kalupahana","year":"2024","journal-title":"Acta Physiol (Oxford)"},{"key":"10.1016\/j.cellsig.2024.111426_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.biopha.2017.07.091","article-title":"Renin-angiotensin-aldosterone (RAAS): the ubiquitous system for homeostasis and pathologies","volume":"94","author":"Patel","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0020","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/01.CIR.56.5.691","article-title":"Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension","volume":"56","author":"Zanchetti","year":"1977","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0025","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCRESAHA.113.301077","article-title":"Discovery and characterization of alamandine: a novel component of the renin-angiotensin system","volume":"112","author":"Lautner","year":"2013","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0030","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/HYPERTENSIONAHA.123.21364","article-title":"Alternative Renin-Angiotensin System","volume":"81","author":"Bader","year":"2024","journal-title":"Hypertension"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/hr.2009.74","article-title":"Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis","volume":"32","author":"Iwai","year":"2009","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.1976.56.1.1","article-title":"Mechanisms regulating renin release","volume":"56","author":"Davis","year":"1976","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0045","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1124\/pr.114.010454","article-title":"International union of basic and clinical pharmacology. XCIX. Angiotensin receptors: interpreters of pathophysiological Angiotensinergic stimuli [corrected]","volume":"67","author":"Karnik","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0055","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS Axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"issue":"Pt A","key":"10.1016\/j.cellsig.2024.111426_bb0060","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","article-title":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","volume":"125","author":"Li","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0065","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.cellsig.2024.111426_bb0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.phrs.2016.03.018","article-title":"ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis","volume":"107","author":"Sim\u00f5es","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.cellsig.2024.111426_bb0075","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1042\/CS20100432","article-title":"Renin, (pro)renin and receptor: an update","volume":"120","author":"Nguyen","year":"2011","journal-title":"Clin. Sci. (Lond.)"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0085","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1681\/ASN.2006010029","article-title":"Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice","volume":"17","author":"Ichihara","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0090","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.2277","article-title":"Cellular and molecular mechanisms of fibrosis","volume":"214","author":"Wynn","year":"2008","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0095","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0165-0173(97)00019-2","article-title":"Important role for angiotensin III and IV in the brain renin-angiotensin system","volume":"25","author":"Wright","year":"1997","journal-title":"Brain Res. Brain Res. Rev."},{"issue":"21","key":"10.1016\/j.cellsig.2024.111426_bb0100","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1007\/s00018-004-4246-1","article-title":"The angiotensin IV\/AT4 receptor","volume":"61","author":"Chai","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cellsig.2024.111426_bb0105","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.matbio.2020.04.005","article-title":"Targeting the renin-angiotensin-aldosterone system in fibrosis","volume":"91-92","author":"AlQudah","year":"2020","journal-title":"Matrix Biol."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0110","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1164\/ajrccm.161.6.9907004","article-title":"Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor","volume":"161","author":"Marshall","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cellsig.2024.111426_bb0115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13069-015-0023-z","article-title":"Modulation of angiotensin II signaling in the prevention of fibrosis","volume":"8","author":"Murphy","year":"2015","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111426_bb0120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2012.4604","article-title":"Angiotensin II-induced production of mitochondrial reactive oxygen species: potential mechanisms and relevance for cardiovascular disease","volume":"19","author":"Dikalov","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.cellsig.2024.111426_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105924","article-title":"Renin angiotensin aldosterone system in pulmonary fibrosis: pathogenesis to therapeutic possibilities","volume":"174","author":"Gupta","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cellsig.2024.111426_bb0130","article-title":"Pirfenidone controls the feedback loop of the AT1R\/p38 MAPK\/renin-angiotensin system axis by regulating liver X receptor-\u03b1 in myocardial infarction-induced cardiac fibrosis","volume":"7","author":"Li","year":"2017","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.cellsig.2024.111426_bb0135","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/hep4.1434","article-title":"Liver-targeted angiotensin converting enzyme 2 therapy inhibits chronic biliary fibrosis in multiple drug-resistant gene 2-knockout mice","volume":"3","author":"Rajapaksha","year":"2019","journal-title":"Hepatol. Commun."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0140","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.27117","article-title":"Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis","volume":"60","author":"Granzow","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/bph.12159","article-title":"ACE2, angiotensin-(1-7) and mas receptor axis in inflammation and fibrosis","volume":"169","author":"Sim\u00f5es e Silva","year":"2013","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0150","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00109-012-0859-2","article-title":"Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury","volume":"90","author":"Rey-Parra","year":"2012","journal-title":"J. Mol. Med. (Berl)"},{"issue":"19","key":"10.1016\/j.cellsig.2024.111426_bb0155","doi-asserted-by":"crossref","first-page":"20363","DOI":"10.1074\/jbc.M314172200","article-title":"Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK","volume":"279","author":"Jiang","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0160","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cvr\/cvn354","article-title":"Does reversal of oxidative stress and inflammation provide vascular protection?","volume":"81","author":"Koh","year":"2009","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.pharmthera.2010.11.001","article-title":"Endothelium-derived vasoactive agents, AT1 receptors and inflammation","volume":"131","author":"MacKenzie","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111426_bb0170","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1161\/01.ATV.0000175295.09607.18","article-title":"Caveolin-1 is essential for activation of Rac1 and NAD(P)H oxidase after angiotensin II type 1 receptor stimulation in vascular smooth muscle cells: role in redox signaling and vascular hypertrophy","volume":"25","author":"Zuo","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0175","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/cvr\/cvq076","article-title":"The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation","volume":"86","author":"Brasier","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.cellsig.2024.111426_bb0180","article-title":"Activation of the renin-angiotensin system promotes colitis development","volume":"6","author":"Shi","year":"2016","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111426_bb0185","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","article-title":"Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2","volume":"126","author":"Gheblawi","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.cellsig.2024.111426_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2019.104350","article-title":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway","volume":"113","author":"Ye","year":"2020","journal-title":"Exp. Mol. Pathol."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0195","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02638-2017","article-title":"A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension","volume":"51","author":"Hemnes","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0200","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","article-title":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome","volume":"21","author":"Khan","year":"2017","journal-title":"Crit. Care"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0205","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10741-019-09855-5","article-title":"The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure","volume":"25","author":"Pugliese","year":"2020","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41392-023-01430-7","article-title":"Signaling pathways in vascular function and hypertension: molecular mechanisms and therapeutic interventions","volume":"8","author":"Ma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0215","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/pharmrev.120.000096","article-title":"Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies","volume":"73","author":"Xu","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0220","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.HYP.19.5.442","article-title":"Nitric oxide inactivates endothelium-derived contracting factor in the rat aorta","volume":"19","author":"Auch-Schwelk","year":"1992","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0225","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/bjp.2008.256","article-title":"Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat","volume":"155","author":"Michel","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0230","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pharmthera.2005.11.001","article-title":"Cardiovascular endothelins: essential regulators of cardiovascular homeostasis","volume":"111","author":"Brunner","year":"2006","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0235","first-page":"129","article-title":"Endothelin-1 induces functionally active CD40 protein via nuclear factor-kappaB in human vascular smooth muscle cells","volume":"12","author":"Browatzki","year":"2007","journal-title":"Eur. J. Med. Res."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0240","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pharmthera.2009.02.006","article-title":"Prostanoids and reactive oxygen species: team players in endothelium-dependent contractions","volume":"122","author":"Tang","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0245","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/ehjcvp\/pvu023","article-title":"Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats","volume":"1","author":"Ruiz-Hurtado","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0250","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","article-title":"The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease","volume":"116","author":"Brewster","year":"2004","journal-title":"Am. J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0255","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbadis.2016.07.019","article-title":"The renin angiotensin system, oxidative stress and mitochondrial function in obesity and insulin resistance","volume":"1863","author":"Ramalingam","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0260","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1467-789X.2011.00942.x","article-title":"The renin-angiotensin system: a link between obesity, inflammation and insulin resistance","volume":"13","author":"Kalupahana","year":"2012","journal-title":"Obes. Rev."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0265","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ejim.2010.06.001","article-title":"Renin angiotensin system polymorphisms in patients with metabolic syndrome (MetS)","volume":"21","author":"Procopciuc","year":"2010","journal-title":"Eur. J. Intern. Med."},{"issue":"12","key":"10.1016\/j.cellsig.2024.111426_bb0270","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jnutbio.2013.07.002","article-title":"The renin-angiotensin system in adipose tissue and its metabolic consequences during obesity","volume":"24","author":"Frigolet","year":"2013","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.cellsig.2024.111426_bb0275","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.2147\/DMSO.S257797","article-title":"Endoplasmic reticulum (ER) stress in part mediates effects of angiotensin II in pancreatic Beta cells","volume":"13","author":"Ramalingam","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073876","article-title":"Neuroprotection in stroke-focus on the renin-angiotensin system: a systematic review","volume":"23","author":"Andone","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellsig.2024.111426_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102200","article-title":"The classical and non-classical axes of renin-angiotensin system in Parkinson disease: the bright and dark side of the moon","volume":"94","author":"Al-Kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.cellsig.2024.111426_bb0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101612","article-title":"Targeting brain renin-angiotensin system for the prevention and treatment of Alzheimer\u2019s disease: past, present and future","volume":"77","author":"Gouveia","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.cellsig.2024.111426_bb0295","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.parkreldis.2022.10.019","article-title":"Renin-angiotensin system blockers affect cognitive decline in Parkinson\u2019s disease: the PPMI dataset","volume":"105","author":"Yang","year":"2022","journal-title":"Parkinsonism Relat. Disord."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0300","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s11357-020-00231-y","article-title":"Brain angiotensin II and angiotensin IV receptors as potential Alzheimer's disease therapeutic targets","volume":"42","author":"Royea","year":"2020","journal-title":"Geroscience"},{"key":"10.1016\/j.cellsig.2024.111426_bb0305","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41531-020-00123-0","article-title":"COVID-19 and possible links with Parkinson's disease and parkinsonism: from bench to bedside","volume":"6","author":"Sulzer","year":"2020","journal-title":"NPJ Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0310","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00401-019-02098-6","article-title":"ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"139","author":"Evans","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"21","key":"10.1016\/j.cellsig.2024.111426_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21217943","article-title":"Regulation of male fertility by the renin-angiotensin system","volume":"21","author":"Gianzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6527","key":"10.1016\/j.cellsig.2024.111426_bb0320","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/375146a0","article-title":"Male-female differences in fertility and blood pressure in ACE-deficient mice","volume":"375","author":"Krege","year":"1995","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0325","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/nm1105-1140","article-title":"Male fertility is dependent on dipeptidase activity of testis ACE","volume":"11","author":"Fuchs","year":"2005","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0330","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1095\/biolreprod.113.114827","article-title":"Human sperm devoid of germinal angiotensin-converting enzyme is responsible for total fertilization failure and lower fertilization rates by conventional in vitro fertilization","volume":"90","author":"Li","year":"2014","journal-title":"Biol. Reprod."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0335","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1043-2760(97)00039-8","article-title":"The role of angiotensin-converting enzyme in blood pressure control, renal function, and male fertility","volume":"8","author":"Esther","year":"1997","journal-title":"Trends Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0340","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1016\/S0021-9258(18)60680-5","article-title":"Angiotensin II receptors and inhibitory actions in Leydig cells","volume":"263","author":"Khanum","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2024.111426_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1235418","article-title":"Unraveling the relationship between the renin-angiotensin system and endometrial cancer: a comprehensive review","volume":"13","author":"Khan","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellsig.2024.111426_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1080285","article-title":"Physiological and pathological roles of Ang II and Ang- (1-7) in the female reproductive system","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"12","key":"10.1016\/j.cellsig.2024.111426_bb0355","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1007\/s10815-020-01971-8","article-title":"Three polymorphisms of renin-angiotensin system and preeclampsia risk","volume":"37","author":"Wang","year":"2020","journal-title":"J. Assist. Reprod. Genet."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0360","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pharmthera.2013.11.002","article-title":"The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease","volume":"142","author":"Giese","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0365","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/ceo.12546","article-title":"Hydration, fluid regulation and the eye: in health and disease","volume":"43","author":"Sherwin","year":"2015","journal-title":"Clin. Experiment. Ophthalmol."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111426_bb0370","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1167\/iovs.06-1473","article-title":"Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway","volume":"48","author":"Nagai","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0375","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIRCRESAHA.122.322003","article-title":"Maintenance of enteral ACE2 prevents diabetic retinopathy in type 1 diabetes","volume":"132","author":"Prasad","year":"2023","journal-title":"Circ. Res."},{"issue":"7408","key":"10.1016\/j.cellsig.2024.111426_bb0380","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature11228","article-title":"ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation","volume":"487","author":"Hashimoto","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0385","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1053\/j.gastro.2020.05.048","article-title":"Alterations in gut microbiota of patients with COVID-19 during time of hospitalization","volume":"159","author":"Zuo","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0390","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1053\/j.gastro.2020.05.034","article-title":"Associations between angiotensin-converting enzyme inhibitors and angiotensin II receptor blocker use, gastrointestinal symptoms, and mortality among patients with COVID-19","volume":"159","author":"Tan","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0395","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2036.2011.04971.x","article-title":"Review article: the pathophysiological roles of the renin-angiotensin system in the gastrointestinal tract","volume":"35","author":"Garg","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0400","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1748-1716.2010.02165.x","article-title":"The renin-angiotensin system and the gastrointestinal mucosa","volume":"201","author":"F\u00e4ndriks","year":"2011","journal-title":"Acta Physiol (Oxford)"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0405","doi-asserted-by":"crossref","first-page":"G355","DOI":"10.1152\/ajpgi.00099.2021","article-title":"Gut microbiota and renin-angiotensin system: a complex interplay at local and systemic levels","volume":"321","author":"Jaworska","year":"2021","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0410","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/gutjnl-2019-318512","article-title":"Imbalance of the renin-angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?","volume":"69","author":"Garg","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0415","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/092986712803413953","article-title":"Novel concept in the mechanism of injury and protection of gastric mucosa: role of renin-angiotensin system and active metabolites of angiotensin","volume":"19","author":"Brzozowski","year":"2012","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.cellsig.2024.111426_bb0420","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.coph.2014.08.007","article-title":"Role of renin-angiotensin system and metabolites of angiotensin in the mechanism of gastric mucosal protection","volume":"19","author":"Brzozowski","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0425","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCRESAHA.119.315743","article-title":"Bone marrow-derived cells restore functional integrity of the gut epithelial and vascular barriers in a model of diabetes and ACE2 deficiency","volume":"125","author":"Duan","year":"2019","journal-title":"Circ. Res."},{"issue":"9386","key":"10.1016\/j.cellsig.2024.111426_bb0430","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.cellsig.2024.111426_bb0435","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS study group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"10244","key":"10.1016\/j.cellsig.2024.111426_bb0440","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cellsig.2024.111426_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24097719","article-title":"Mineralocorticoid receptor antagonists for preventing chronic kidney disease progression: current evidence and future challenges","volume":"24","author":"Fujii","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0450","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical Management of Hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin. Proc."},{"issue":"15","key":"10.1016\/j.cellsig.2024.111426_bb0455","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.2165\/11204360-000000000-00000","article-title":"Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension","volume":"70","author":"Duggan","year":"2010","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.cellsig.2024.111426_bb0460","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0465","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-8587(15)00469-6","article-title":"Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial","volume":"4","author":"Heerspink","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0470","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/ejhf.973","article-title":"Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial","volume":"20","author":"Vaduganathan","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0475","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ejhf.896","article-title":"Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial","volume":"20","author":"Kristensen","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"16","key":"10.1016\/j.cellsig.2024.111426_bb0480","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, Enalapril, or Aliskiren and Enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.cellsig.2024.111426_bb0485","doi-asserted-by":"crossref","first-page":"10882","DOI":"10.1021\/acs.jmedchem.2c00834","article-title":"Discovery of SPH3127: a novel, highly potent, and orally active direct renin inhibitor","volume":"65","author":"Iijima","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0490","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41440-024-01657-z","article-title":"A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension","volume":"47","author":"Wang","year":"2024","journal-title":"Hypertens. Res."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0495","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"issue":"11 Suppl","key":"10.1016\/j.cellsig.2024.111426_bb0500","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am. J. Manag. Care"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0505","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: a population-based cohort study","volume":"80","author":"Leon","year":"2022","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0510","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"10208","key":"10.1016\/j.cellsig.2024.111426_bb0515","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0520","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.kint.2023.09.012","article-title":"Evaluation of the stopping angiotensin converting enzyme inhibitor compared to angiotensin receptor blocker (STOP ACEi trial) in advanced and progressive chronic kidney disease","volume":"105","author":"Bhandari","year":"2024","journal-title":"Kidney Int."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111426_bb0525","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur. J. Heart Fail."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0530","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1002\/ejhf.3304","article-title":"Cardiovascular-kidney-metabolic overlap in heart failure with preserved ejection fraction: cardiac structure and function, clinical outcomes, and response to sacubitril\/valsartan in PARAGON-HF","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"24","key":"10.1016\/j.cellsig.2024.111426_bb0535","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.cellsig.2024.111426_bb0540","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cellsig.2024.111426_bb0545","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0550","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","article-title":"Double-blind randomized phase 3 study comparing Esaxerenone (CS-3150) and Eplerenone in patients with essential hypertension (ESAX-HTN study)","volume":"75","author":"Ito","year":"2020","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0555","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0560","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin. Exp. Nephrol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0565","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"issue":"12","key":"10.1016\/j.cellsig.2024.111426_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145666","article-title":"Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628","volume":"10","author":"Ma","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0575","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2213169","article-title":"Phase 2 trial of Baxdrostat for treatment-resistant hypertension","volume":"388","author":"Freeman","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.cellsig.2024.111426_bb0580","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/jama.2023.16029","article-title":"Aldosterone synthase inhibition with Lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial","volume":"330","author":"Laffin","year":"2023","journal-title":"Jama"},{"issue":"10424","key":"10.1016\/j.cellsig.2024.111426_bb0585","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0590","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.119.040070","article-title":"Efficacy and safety of Firibastat, a first-in-class brain aminopeptidase a inhibitor, in hypertensive overweight patients of multiple ethnic origins","volume":"140","author":"Ferdinand","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0595","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1161\/HYPERTENSIONAHA.118.12499","article-title":"NI956\/QGC006, a potent orally active, brain-penetrating aminopeptidase a inhibitor for treating hypertension","volume":"73","author":"Keck","year":"2019","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.cellsig.2024.111426_bb0600","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"Jama"},{"key":"10.1016\/j.cellsig.2024.111426_bb0605","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.biopha.2017.04.024","article-title":"Neprilysin inhibitors: a new hope to halt the diabetic cardiovascular and renal complications?","volume":"90","author":"Malek","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0610","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0008-6363(01)00238-3","article-title":"The role of the natriuretic peptides in the cardiovascular system","volume":"51","author":"Suzuki","year":"2001","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0615","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.cellsig.2024.111426_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: diagnostic and therapeutic implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"8663","key":"10.1016\/j.cellsig.2024.111426_bb0625","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0140-6736(89)90714-9","article-title":"Effects of UK 69 578: a novel atriopeptidase inhibitor","volume":"2","author":"Northridge","year":"1989","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0630","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00004872-199207000-00002","article-title":"Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension","volume":"10","author":"Bevan","year":"1992","journal-title":"J. Hypertens."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111426_bb0635","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1681\/ASN.V12102051","article-title":"Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone","volume":"12","author":"Taal","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"issue":"9230","key":"10.1016\/j.cellsig.2024.111426_bb0640","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0140-6736(00)02596-4","article-title":"Vasopeptidase inhibition and angio-oedema","volume":"356","author":"Messerli","year":"2000","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0645","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the Omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0650","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat versus Enalapril randomized trial of utility in reducing events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0655","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2014.05.002","article-title":"Current role of neprilysin inhibitors in hypertension and heart failure","volume":"144","author":"von Lueder","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0660","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0665","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"Efficacy and safety of Sacubitril\/valsartan in high-risk patients in the PIONEER-HF trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ. Heart Fail."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111426_bb0670","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","article-title":"Sacubitril\/valsartan: Neprilysin inhibition 5 years after PARADIGM-HF","volume":"8","author":"Docherty","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0675","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029565","article-title":"Updates for cardio-kidney protective effects by angiotensin receptor-Neprilysin inhibitor: requirement for additional evidence of kidney protection","volume":"12","author":"Tsukamoto","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0680","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1053\/j.ajkd.2022.04.016","article-title":"Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms","volume":"80","author":"Epstein","year":"2022","journal-title":"Am. J. Kidney Dis."},{"issue":"31","key":"10.1016\/j.cellsig.2024.111426_bb0685","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","article-title":"Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"43","author":"Pandey","year":"2022","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0690","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0695","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","article-title":"Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Sueta","year":"2020","journal-title":"Curr. Hypertens. Rep."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0700","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259485","article-title":"Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: a retrospective study","volume":"16","author":"Iwahana","year":"2021","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0705","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193380","article-title":"Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion","volume":"13","author":"Bamberg","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0710","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/acs.jmedchem.8b01523","article-title":"Identification of mineralocorticoid receptor modulators with low impact on electrolyte homeostasis but maintained organ protection","volume":"62","author":"Granberg","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.cellsig.2024.111426_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cellsig.2024.111426_bb0720","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.604928","article-title":"The non-steroidal mineralocorticoid receptor antagonist KBP-5074 limits albuminuria and has improved therapeutic index compared with Eplerenone in a rat model with mineralocorticoid-induced renal injury","volume":"12","author":"Jaisser","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0725","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1681\/ASN.2014121216","article-title":"Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia","volume":"27","author":"Barrera-Chimal","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2024.111426_bb0730","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116521","article-title":"Emerging trends in small molecule inhibitors targeting aldosterone synthase: a new paradigm in cardiovascular disease treatment","volume":"274","author":"Guo","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0735","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","article-title":"Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2)","volume":"69","author":"Bogman","year":"2017","journal-title":"Hypertension"},{"issue":"35","key":"10.1016\/j.cellsig.2024.111426_bb0740","doi-asserted-by":"crossref","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","article-title":"Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta)","volume":"264","author":"Mornet","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0745","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065782","article-title":"Molecular and epigenetic control of aldosterone synthase, CYP11B2 and 11-hydroxylase, CYP11B1","volume":"24","author":"Takeda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101918","article-title":"Baxdrostat: a novel aldosterone synthase inhibitor for treatment resistant hypertension","volume":"48","author":"Dogra","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111426_bb0755","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bph.16247","article-title":"Taming resistant hypertension: the promise of novel pharmacologic approaches and renal denervation","volume":"181","author":"Azzam","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0760","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","article-title":"Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers","volume":"46","author":"Freeman","year":"2023","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0765","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/dom.15518","article-title":"Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: a multicentre, randomized, double-blind, placebo-controlled, phase I trial","volume":"26","author":"Bornstein","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0770","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.116.236463","article-title":"Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman Primates","volume":"359","author":"Weldon","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111426_bb0775","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11906-019-0957-4","article-title":"Orally active aminopeptidase a inhibitor prodrugs: current state and future directions","volume":"21","author":"Keck","year":"2019","journal-title":"Curr. Hypertens. Rep."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/ajm.ajm_117_20","article-title":"Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: a review of clinical trials","volume":"11","author":"Alomar","year":"2021","journal-title":"Avicenna J. Med."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111426_bb0785","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cjca.2020.03.005","article-title":"Targeting brain aminopeptidase a: a new strategy for the treatment of hypertension and heart failure","volume":"36","author":"Marc","year":"2020","journal-title":"Can. J. Cardiol."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0790","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40262-013-0125-y","article-title":"Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase a inhibitor prodrug","volume":"53","author":"Balavoine","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0795","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1097\/HJH.0000000000002092","article-title":"A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase a inhibitor, firibastat, in hypertension","volume":"37","author":"Azizi","year":"2019","journal-title":"J. Hypertens."},{"issue":"10304","key":"10.1016\/j.cellsig.2024.111426_bb0800","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2024.111426_bb0805","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fphar.2017.00100","article-title":"Current situation of medication adherence in hypertension","volume":"8","author":"Vrijens","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111426_bb0810","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyae027","article-title":"Risk factors for uncontrolled blood pressure among individuals with hypertension on treatment: the CONSTANCES population-based study","volume":"53","author":"Cherfane","year":"2024","journal-title":"Int. J. Epidemiol."},{"issue":"20","key":"10.1016\/j.cellsig.2024.111426_bb0815","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027694","article-title":"Small interfering RNA therapeutics in hypertension: a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen-targeting small interfering RNA","volume":"11","author":"Ranasinghe","year":"2022","journal-title":"J. Am. Heart Assoc."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0820","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111426_bb0825","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1053\/j.ajkd.2022.03.015","article-title":"Renal denervation: a review","volume":"80","author":"Rey-Garc\u00eda","year":"2022","journal-title":"Am. J. Kidney Dis."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0830","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrcardio.2010.85","article-title":"Novel therapeutic targets for hypertension","volume":"7","author":"Paulis","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111426_bb0835","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2022.01.017","article-title":"Trends and outcomes of left ventricular assist device therapy: JACC focus seminar","volume":"79","author":"Varshney","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0840","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","article-title":"Clinical outcomes and response to Vericiguat according to index heart failure event: insights from the VICTORIA trial","volume":"6","author":"Lam","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"15","key":"10.1016\/j.cellsig.2024.111426_bb0845","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/jama.2020.15922","article-title":"Effect of Vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial","volume":"324","author":"Armstrong","year":"2020","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0850","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000486401","article-title":"Restless legs syndrome: an unresolved uremic disorder after renal transplantation","volume":"139","author":"Calvi\u00f1o","year":"2018","journal-title":"Nephron"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111426_bb0855","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41587-022-01359-2","article-title":"CRISPR technology","volume":"40","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111426_bb0860","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142500","article-title":"Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy","volume":"131","author":"Raas","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0865","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2009030300","article-title":"The biology of the (pro)renin receptor","volume":"21","author":"Nguyen","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0870","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111426_bb0875","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","article-title":"Signaling pathways of chronic kidney diseases, implications for therapeutics","volume":"7","author":"Yuan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.cellsig.2024.111426_bb0880","doi-asserted-by":"crossref","first-page":"8624","DOI":"10.7150\/thno.48561","article-title":"Angiotensin IV attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy, apoptosis and fibrosis","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.cellsig.2024.111426_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155785","article-title":"Minireview: understanding and targeting inflammatory, hemodynamic and injury markers for cardiorenal protection in type 1 diabetes","volume":"153","author":"Kugathasan","year":"2024","journal-title":"Metabolism"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824003942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824003942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:09:27Z","timestamp":1734624567000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656824003942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":177,"alternative-id":["S0898656824003942"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111426","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The renin-angiotensin-aldosterone system: An old tree sprouts new shoots","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111426"}}